PROCEPT BioRobotics Corporation (PRCT)

Market Cap	1.03B -47.7%
Revenue (ttm)	337.34M +22.7%
Net Income	-109.76M
EPS	-1.95
Shares Out	57.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,149,519
Open	17.63
Previous Close	17.51
Day's Range	17.63 - 18.46
52-Week Range	16.67 - 38.11
Beta	0.92
Analysts	Hold
Price Target	22.42 (+25.18%)
Est. Earnings	Nov 3, 2026

About PRCT

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hype...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 15, 2021
• Employees: 888
• Stock Exchange: Nasdaq
• Ticker Symbol: PRCT
• Website: https://www.procept-biorobotics.com

Financial Performance

In 2025, PROCEPT BioRobotics's revenue was $308.05 million, an increase of 37.22% compared to the previous year's $224.50 million. Losses were -$95.57 million, 4.55% more than in 2024.

Analyst Summary

According to 15 analysts, the average rating for PRCT stock is "Hold." The 12-month stock price target is $22.42, which is an increase of 25.18% from the latest price.

Price Target

$22.42

(25.18% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 8, 2026

Data Sources Report a data error